Split-CAR approaches using dual adaptors against distinct antigens have yielded AND-gated AdCARs for glioblastoma (EGFR/GD2), colorectal cancer (CEA/EpCAM), and AML (CD33/CD123).259. Here, CD33 is linked to acute myeloid leukemia.